A good event drawing a good cross functional group together.
Steve RichmondAstraZeneca
- Why oncology market access models must evolve
The proliferation of stakeholders makes oncology market access increasingly complex—and successful models increasingly essential. Peter Mansell reports.
9:59am, 7th Sep 2010 - Comprehensive strategies for market access
Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers.
9:51am, 7th Sep 2010 - Market access: Risk sharing and alternative pricing schemes
Shared-risk agreements can represent uncertain rewards for drug makers and payers. What you need to know before entering into one.
2:33pm, 10th Aug 2010
Day 1 // Conference Agenda
June 2, 2010
Session 1: Market Access, Pricing & Reimbursement
8:00 am Registration Coffee
9:00 am Chairman’s Address
Cyrus Chowdhury, Vice President, Global Market Access, Insight Strategy Advisors
9:10 am How to work with your regulatory team
• Discover how to navigate your brand through the FDA, find out what the restrictions and differentiate yourself
• Break the silos within your company and learn to communicate with all involved teams
• Find out what the role of regulatory is and who should get involved in Market Access planning
Dirk Haasner, Vice President External Scientific Affairs, Lundbeck
9:50 am Maximize patient access and supply chain strategies
• Case study: Medication Possession Ratio
• Patient access solutions
• Maximizing the supply chain in specialty drugs
Rob Osborne, Sr. Director, Specialty Pharma Sales, CuraScript Pharmacy
10:30 am Break & Exhibition
11:00 am Build trust and transactions with payers
• Identify where your organization is “mapped to win” in building sustainable relationships with payers
• Deepen your understanding of the roles, needs and wants of various stakeholders inside payer organizations
• Broaden your thinking about what ‘value’ can mean – and how you can enhance it
• Ideate with your peers on an actionable targeted relationship marketing program
Karen Carr, Vice President, Strategic Growth & Innovation, imc2 health & wellness
Session 2: REMS & Risk Management
11:40 am Maximize Your Risk Evaluation and Mitigation Strategy (REMS)
• What is REMS and how does it impact key marketplace stakeholders?
• Understand the current landscape and trends
• Learn how to optimize the balance of patient access, medication safety and the burden on the healthcare delivery system
Heather Gagnier, Director, Risk Management and Commercial Services, UBC
12:20 pm Lunch & Exhibition
1:30 pm Risk Communication: Collaboration to Create a Value Opportunity
• Identifying the key messages related to a specific product risk
• Developing an effective risk communication strategy using a variety of tools and resources
• Implementing a comprehensive risk communication program globally
Carla Perdun Barrett, Senior Director & Head, Safety Sciences Research, Worldwide Safety Strategy, Pfizer
2:10 pm A balanced approach to Risk Management and REMS planning: achieving clinical and commercial objectives
• Situation: unnecessary gap between Risk Mitigation and Commercial Objectives
• Principles and methods: achieving a balanced approach
• Future: promising findings and cutting-edge trends
Jeffrey Fetterman, CEO, ParagonRx
2:50 pm Break & Exhibition
3:20 pm REMS Implementation: Steps to Consider
• Coordinating the implementation process
• Cross functionality of the implementation process
• REMS and non-REMS considerations throughout the implementation process
Heather Schiappacasse, Director US Risk Identification, Surveillance and Communication, sanofi aventis
4:00 pm Early and innovative pricing strategy
• Understand the difference between a price and a pricing strategy
• When should you start thinking about pricing and why?
• Determining what your strategy plans to optimize – profit, sales or market share?
• Gathering data to support a product value message and the price and reimbursement status
Erik Schultz, Vice President, US Pricing and Market Access, HERON Evidence Development
4:40 pm Chairman’s closing remarks
4:50 pm Networking Drinks in the Exhibition area
6:00 pm End of Day 1
Day 2 // Conference Agenda
June 3, 2010
8:30 am Registration Coffee
9:00 am Chairman’s Address
Jeffrey Fetterman, CEO, ParagonRx
9:10 am Achieving integrated market access opportunities in the commercial plan, challenges and opportunities.
• Overview of challenges facing organizations in integrating market access into the commercial model.
• Strategies for increasing pull-through success in sales and marketing efforts.
• Building integrated teams to deliver real brand value to customers.
John Vieira, Senior Director, Marketing Operations and Strategic Marketing, Daiichi Sankyo
Session 3: Payer Relations
9:50 am Payer engagement- Collaborating with payer and channel to optimize product success.
• Identify the appropriate stakeholders to set up collaborations
• Utilize those relationships to assess your strategies
• Discover how to use your value proposition to gain “buy-in”
Jeff Christensen, Senior Manager, Managed Markets, Azur Pharma
10:30 am Break & Exhibition
11:00 am Maximizing Access with your Federal Customers
• Find out how to leverage key touch points with your customers
• Discover how to leverage customer access policy and the new rules of engagement
• Best practice guide for executing pull-base sales model
Kevin J. Brown, Senior Manager, Government Accounts – DoD/VA, Astellas Pharma
11:40 am Payer Marketing: Creating Value in a Rapidly Evolving Market Segment
• Understand the payer value proposition & how you can leverage it to gain brand access
• Create organizational excellence to optimize the payer marketing model
• Build a sound platform for launching effective payer marketing campaigns
Drew Desjardins, Executive Director, Brand Payer Marketing, Pfizer
Session 4: Health Economics & Outcomes Research
12:20 pm HEOR – the customer way
• Discover the importance of linking up with the end user
• Find out what your customer needs and feed your research results back in the approach you take for higher credibility level
• Getting your data outcomes information through legal – the battle of on and off label
Todd Williamson, Vice President, Health Economics & Outcomes Research, Bayer
12:30 pm Lunch & Exhibition
1:30 pm Health Technology Assessment (HTA) and preparing for the access challenge
• Outline examples of the current access challenges created by HTA
• Discuss the tactical challenges for addressing HTA in a global pharmaceutical company
• Discuss key considerations in order to achieve success
Lee Bowman, Research Fellow, Global Health Outcomes Research, Eli Lilly
2:10 pm Product Value Demonstration in the Eyes of Stakeholders
• Demonstrate different values to disconnected stakeholder with different incentives
• Tie product value to healthcare quality improvement
• Let customers see their own data
Jay Lin, Director, Evidence Based Medicine, sanofi Aventis (former)
2:50 pm Chairman’s closing remarks
3:00 pm End of conference
